UTHR - ユナイテッド・セラピュ―ティクス (United Therapeutics Corporation)

UTHRのニュース

   United Therapeutics Corp (UTHR) EVP & General Counsel Paul A Mahon Sold $1.3 million of Shares  2021/09/03 00:15:03 GuruFocus
Related Stocks: UTHR ,
   Jefferies says investors should buy these 23 stocks to outperform in an increasingly nervous market and because they have 135% upside on average  2021/08/22 09:00:00 Business Insider
Summary List Placement The stock market is at all-time highs and COVID-19 cases are ticking higher, and that might be bringing back some uncomfortable memories of early 2020 for investors. Jefferies'' equity research unit says the combination of rising COVID cases, geopolitical issues, and the Fed''s position on monetary policy might make for a tough investing environment, but advises against heading for the exits. "Economic data releases remain generally encouraging and the lack of stepped-up lockdowns in the US suggest that the progression of the recovery has slowed not stalled," the firm wrote. "This change of pace provides an opening for outperformance based on single stock selection." The firm says it sees three broad categories of winners that could prove to be severely undervalued if they are able to achieve their aims and if economic progress continues. Those categories are companies with specific catalysts, companies benefiting from structural growth, and those that should outperform because they''re so highly levered to the recovery. "Companies with more leverage to the economic cycle have seen share prices largely tumble, despite generally solid 2Q results and positive revisions," said Jefferies. "Consequently, many of these companies now appear substantially cheaper than earlier in 2021, when stock prices were loftier and Street forecasts much lower." Others are struggling for more individualized reasons, although some of those are also linked to the effects of the pandemic.
   UNITED THERAPEUTICS Corp (UTHR): Price Up $2.65 (1.3)% Over Past Day, Up $2.03 (0.99)% Over Past Hour  2021/08/18 15:18:42 ETF Daily News
Regarding the trend, note that the strongest trend exists on the 50 hour timeframe. The post UNITED THERAPEUTICS Corp (UTHR): Price Up $2.65 (1.3)% Over Past Day, Up $2.03 (0.99)% Over Past Hour appeared first on ETF Daily News .
   MannKind and United Therapeutics ink supply agreement for Tyvaso and BluHale  2021/08/16 11:26:10 Seeking Alpha
   Exosome Therapeutic Market Astonishing Growth with Top Influencing Key Players like evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences  2021/08/06 18:09:54 OpenPR
An international Exosome Therapeutic Market report is the best source that gives CAGR values with variations during the forecast period of 2021-2028 for the market. The study encompasses market drivers and restraints by using SWOT analysis, along with their impact
   How an under-the-radar eVTOL startup convinced UPS its technology was ready to remake e-commerce logistics  2021/04/12 11:36:00 Business Insider
Summary List Placement UPS knew it wanted to buy into electric vertical takeoff and landing aircraft before it met with a single company building the technology. So when electric vertical takeoff and landing aircraft, better-known as, eVTOL, startup Beta Technologies CEO Kyle Clark met with Bala Ganesh, vice president for engineering at UPS, for the first time, he didn't need to convince him of the merits of the technology. He needed to convince him that Beta was ready. Clark's strategy was simple: Get out of the conference room and into the air. "When he showed up at Beta, I jumped in the helicopter with him and said, 'Hey, let's go see flight tests.' And his eyes got nice and big and he was jazzed because he wasn't looking at a PowerPoint slide, or a paper airplane," Clark told Insider. UPS has agreed to purchase 10 Beta aircraft , with the option for 150 more, to speed up and simplify elements of its package delivery network. UPS announced the deal last week and the terms were not di closed.
   Wedbush Stick to Their Buy Rating for United Therapeutics By Investing.com  2021/04/05 17:45:04 Investing.com
Wedbush Stick to Their Buy Rating for United Therapeutics
   Treprostinil Drugs Market Will Hit Big Revenues In Future | United Therapeutics, Novartis, Teva Pharmaceutical Industries Ltd  2021/03/23 10:21:52 OpenPR
Treprostinil is a synthetic prostacyclin prescribed for the treatment of pulmonary arterial hypertension. Treprostinil works as a vasodilator lowering the blood pressure in the pulmonary artery leading from heart to lungs and is known to improve the ability to exercise.
   North America Pulmonary Arterial Hypertension (PAH) Medicine Market is Ready for Speedy Growth | Players – Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation  2021/03/05 13:36:42 OpenPR
This report is an essential reference for who looks for detailed information on North America Pulmonary Arterial Hypertension (PAH) Medicine market. The report covers data on North America markets including historical and future trends for supply, market size, prices, trading,
   Chuck Hull on 3D Systems’ Journey into Bioprinting - 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing  2021/03/05 13:00:21 3DPrint
After 35 years of creating innovative 3D printing technologies, pioneering company 3D Systems (NYSE: DDD) is expanding its bioprinting efforts. Following a successful collaboration with United Therapeutics Corporation dedicated to…
   Treprostinil Drugs Market Will Hit Big Revenues In Future | United Therapeutics, Novartis, Teva Pharmaceutical Industries Ltd  2021/03/23 10:21:52 OpenPR
Treprostinil is a synthetic prostacyclin prescribed for the treatment of pulmonary arterial hypertension. Treprostinil works as a vasodilator lowering the blood pressure in the pulmonary artery leading from heart to lungs and is known to improve the ability to exercise.
   North America Pulmonary Arterial Hypertension (PAH) Medicine Market is Ready for Speedy Growth | Players – Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation  2021/03/05 13:36:42 OpenPR
This report is an essential reference for who looks for detailed information on North America Pulmonary Arterial Hypertension (PAH) Medicine market. The report covers data on North America markets including historical and future trends for supply, market size, prices, trading,
   Chuck Hull on 3D Systems’ Journey into Bioprinting - 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing  2021/03/05 13:00:21 3DPrint
After 35 years of creating innovative 3D printing technologies, pioneering company 3D Systems (NYSE: DDD) is expanding its bioprinting efforts. Following a successful collaboration with United Therapeutics Corporation dedicated to…
   United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback  2021/03/03 14:53:01 Endpoints News
About three years after acquiring SteadyMed and its experimental pulmonary arterial hypertension drug Trevyent, United Therapeutics has decided to kick the program to the curb. In an 8-K form filed with the SEC on Tuesday, United revealed that they are shutting down development of Trevyent after receiving feedback from the
   United Therapeutics Pulls Plug On Trevyent Development - Stocks News Feed  2021/03/03 12:38:16 Stocks News Feed
Based on the FDA’s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent. Trevyent is a drug-device combination product that combines two-day, single-use, disposable PatchPump technology with treprostinil for the subcutaneous treatment of pulmonary arterial hypertension. The comments followed a meeting to discuss the company’s planned resubmission of its marketing application for Trevyent in… Read More »United Therapeutics Pulls Plug On Trevyent Development

calendar